In vitro and in vivo assessment of linezolid combined with ertapenem: a highly synergistic combination against methicillin-resistant Staphylococcus aureus

Antimicrob Agents Chemother. 2006 Jul;50(7):2547-9. doi: 10.1128/AAC.01501-05.

Abstract

Linezolid in combination with ertapenem showed in vitro synergy against methicillin-resistant Staphylococcus aureus strains. We confirmed this interaction in vivo by using a rabbit endocarditis experimental model and simulation of the human pharmacokinetics in animals for both antibiotics. Linezolid plus ertapenem exhibited highly synergistic activity in vivo after 4 days of treatment.

Publication types

  • Research Support, Non-U.S. Gov't

MeSH terms

  • Acetamides* / administration & dosage
  • Acetamides* / pharmacokinetics
  • Acetamides* / pharmacology
  • Acetamides* / therapeutic use
  • Animals
  • Anti-Infective Agents* / administration & dosage
  • Anti-Infective Agents* / pharmacology
  • Anti-Infective Agents* / therapeutic use
  • Drug Synergism
  • Endocarditis, Bacterial* / drug therapy
  • Endocarditis, Bacterial* / microbiology
  • Ertapenem
  • Humans
  • Linezolid
  • Methicillin Resistance*
  • Oxazolidinones* / administration & dosage
  • Oxazolidinones* / pharmacokinetics
  • Oxazolidinones* / pharmacology
  • Oxazolidinones* / therapeutic use
  • Rabbits
  • Staphylococcal Infections / drug therapy
  • Staphylococcus aureus / drug effects*
  • beta-Lactams* / administration & dosage
  • beta-Lactams* / pharmacokinetics
  • beta-Lactams* / pharmacology
  • beta-Lactams* / therapeutic use

Substances

  • Acetamides
  • Anti-Infective Agents
  • Oxazolidinones
  • beta-Lactams
  • Ertapenem
  • Linezolid